You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Science this week: genetic overlap between five psychiatric disorders, and more.
Using post-mortem data, researchers explored similarities and differences between autism, schizophrenia, bipolar disorder, alcoholism, and depression.
Business Insider reports that researchers are making headway in linking genetic variants to mental illness risk.
Genetic testing can help identify why people aren't responding to certain mental health medications, according to the Philadelphia Inquirer.
In the African American arm of a new GWAS, a risk variant in the SEMA3A gene was associated with both alcohol dependence disorder and major depressive disorder.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
Researchers from Hong Kong imputed transcriptomes from GWAS data and compared them to drug-induced gene expression profiles.
NBC News reports that pharmacogenomics can help match people with depression to drugs that may work best for them.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
In Nature this week: the largest known collection of human genetic variants, and more.